Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Front Immunol
; 13: 949140, 2022.
Article
in En
| MEDLINE
| ID: mdl-36052078
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
CD47 Antigen
/
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Limits:
Humans
Language:
En
Journal:
Front Immunol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: